Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 8.24 | 3.00% | 0.24 |
MRNS closed up 3.0 percent on Thursday, September 28, 2023, on 1.32 times normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 3% | about 11 hours ago |
| 50 DMA Support | about 12 hours ago |
| 60 Minute Opening Range Breakdown | about 13 hours ago |
| Fell Below 50 DMA | about 13 hours ago |
| Down 2 % | about 13 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/06/2023
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Ketones Seizure Fragile X Syndrome Sedatives Pregnanes Neurosteroids
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Ketones Seizure Fragile X Syndrome Sedatives Pregnanes Neurosteroids
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.15 |
| 52 Week Low | 3.465 |
| Average Volume | 723,336 |
| 200-Day Moving Average | 7.45 |
| 50-Day Moving Average | 7.89 |
| 20-Day Moving Average | 7.01 |
| 10-Day Moving Average | 7.08 |
| Average True Range | 0.59 |
| RSI (14) | 60.47 |
| ADX | 19.98 |
| +DI | 32.84 |
| -DI | 18.77 |
| Chandelier Exit (Long, 3 ATRs) | 6.50 |
| Chandelier Exit (Short, 3 ATRs) | 7.56 |
| Upper Bollinger Bands | 8.18 |
| Lower Bollinger Band | 5.83 |
| Percent B (%b) | 1.02 |
| BandWidth | 33.53 |
| MACD Line | 0.00 |
| MACD Signal Line | -0.25 |
| MACD Histogram | 0.248 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.18 | ||||
| Resistance 3 (R3) | 9.08 | 8.68 | 9.02 | ||
| Resistance 2 (R2) | 8.68 | 8.44 | 8.72 | 8.97 | |
| Resistance 1 (R1) | 8.46 | 8.29 | 8.57 | 8.55 | 8.92 |
| Pivot Point | 8.05 | 8.05 | 8.11 | 8.10 | 8.05 |
| Support 1 (S1) | 7.83 | 7.81 | 7.94 | 7.93 | 7.56 |
| Support 2 (S2) | 7.43 | 7.67 | 7.47 | 7.51 | |
| Support 3 (S3) | 7.21 | 7.43 | 7.46 | ||
| Support 4 (S4) | 7.30 |
